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I.

CYSTINURIA:

AN OVERVIEW

Introduction
Cystinuria is an autosomal recessive inherited disorder
of cystine and dibasic amino acid transport.

The transport

defect affects the epithelial cells of the renal
the gastrointestinal tract.
amino acids cystine,

lysine,

tubules and

Because of the renal defect,
arginine,

and ornithine are

excreted in great excess in the urine.

Excessive urinary

quantities of cystine,

the

the least soluble of naturally

occuring amino acids, predisposes to the formation of renal,
ureteral,

and bladder calculi.

The major causes of morbidity

and mortality in this disorder are the sequelae of this
stone formation: renal and ureteral colic,
infection,

urinary tract

and compromise of renal function.

The defect

of gastrointestinal tract epithelium is expressed by elevated
stool levels of dibasic amino acids and their breakdown
products.
Historical Landmarks in the Study of Cystinuria
1.

Renal Defect
William Hyde Wollaston,

Society of London,

MD,

Secretary to the Royal

came before that body in July of 1810

to announce a new discovery.
known the existence,

Wollaston wished "to make

and to describe the leading properties

of a new species of urinary calculus for the human bladder."
The English physician had obtained two specimens of the
new material.

The first was from the bladder of a five

4

year old boy - the brother of a colleague.

The second specimen

had been located in the collection of Guy's Hospital - having
been extracted from a thirty-six year old man named William
Small.
Wollaston carefully described the appearance of these
stones.

He found them to be soluble in either strong acid or

alkali.

The physician concluded that the material was
an oxide; and since both the calculi
that have been observed have been taken
from the bladder, it may be convenient
to give it the name of cystic oxide.
which will serve to distinguish it from
other calculi; and as this is unlike any
other term at present employed in chem¬
istry, it is to be hoped that it will not
be thought to require any alteration.1,0

Contrary to Wollaston's wish,

the term "cystic oxide"

did require alteration - for the compoindwas not an oxide.
The name which came to be universally adopted was suggested
by Berzelius:

cystine.

Greek root for bladder
error of physiology.

Unfortunately,
(kystis),

by adopting the

Berzelius perpetuated an

Cystine is excreted by the kidneys

and does not have its origin in the bladder.
In 1824 Stromeyer's discovery of cystine crystalluria
TS

was published.

When,

over sixty years later,

Von Udranszky

and Bauman found cadaverin and putrescine in the excretea
of a cystinuric,

the^suggested that the defect in cystinuria

involved more than that of a single amino acid.
remarked,

in his 1908 Croonian lectures,

Garrod

that the presence

of cadaverin and putrescine in the urine suggested excessive
ut

excretion of lysine and arginine.

This "diaminuria",

he said,

"might be an outcome of the same error of metabolism as
cystinuria-"

Using microbiologic assays, Yeh and his

associates demonstrated marked increases in urinary excre¬
tion of cystine, lysine, and arginine by an eight year
old patient.

Stein later used chromatographic techniques

to confirm Yeh’s findings and added ornithine to the
list of amino acids excreted in excess by cystinurics.'°‘
In their classic 1951 paper, Dent and Rose synthesized
the preceedmg findings by pointing out that cystine,
arginine, lysine, and ornithine each had two amino

(or

guanidine) groups separated by four to six carbon, or
sulfur atoms.

Normally,

these amino acids are filtered

and then reabsorbed in the tubule.

They suggested that

as a result of an inherited defect of
he renal tubules, he (the cystinuric)
is only able to reabsorb from the glou-L"tra^il'tra-te about one-half
of the cystine present, and a small but
unknown proportion of the lysine and
arginine.
These substances are there¬
fore concentrated in the urine to a
degree which may reach, twentyfold of
“J’"The cystine is very insoluble,
and the urine passed is therefore super¬
saturated when excreted, and tends on
to deP?sit the characteristic
ystals, especially when the urine is
acidand the cystine is therefore near
its isoelectric point.***
Dent and Rose's hypothesis had implications beyond its
correct explanation of the aminoaciduria in cystinuria.

The

hypothesis suggested that renal tubular absorption was
accomplished by specific mechanisms directed by the genome.
The idea suggested an entire class of inborn metabolic
diseases:

the "inborn errors of transport."

b

2.

Intestinal Defect
Von Udranszky and Bauman in I889 observed that the

diamines, cadaverine and putrescine, decarboxylation products
of lysine and arginine, were present in large amounts in
the feces of a cystinuria patient.

Garrod mentioned this

observation in his Croonian lectures to support his con¬
cept of biochemical heterogeneity in cystinuria.

Over fifty

years later, Milne performed experiments which demonstrated
an intestinal absorption defect for the dibasic amino acids
m patients with cystinuria.

Asatoor reported additional

experimental evidence in support of an intestinal transport
lesion.

Thier, et al have confirmed this work by in vitro

studies of intestinal transport using jejunal biopsies.'

3.

Genetics
Marcet noted the familial occurrence of cystinuria

eight years after Wollaston's original report*** Later in the
nineteenth century, the chronicity of cystinuria was suggested
in a case reported by Sir Henry Thompson.

Thompson described,

m 1870, an 81 year old man for whom a cystine calculus was
crushed.

The patient had passed a stone of a similar

chemical nature thirty-nine years previously
Gairod appreciated the familial and chronic nature of
the disease and discussed cystinuria among the inborn errors
Ul

of metabolism.

In 1953. Harris and co-workers analysed

patients’ pedigrees, using quantitative urine amino acid
determinations, and concluded that cystinuria is inherited

7

as an autosomal recessive disorder.

The genetics of cys-

tinuria, however, have proven to be more complicated than
simple autosomal recessive inheritance.

Rosenberg and his

colleagues have used various laboratory and clinical
measurements to indicate that cystinuria is at least
three biochemically distinct inheritable diseases.

r

8

C.

Pathophysiology
1. Renal
Cusworth and Dent have demonstrated that normally more
than 99% of filtered amino acids are reabsorbed by the
renal tubule21 (see Figure C-l).
for the most part,

This reabsorption occurs,

in the proximal tubule.

Amino acid

clearances are, therefore, less than 1% of the glomerular
filtration rate (GFR) with two exceptions in man: histidine
(5-10% of GFR) and glycine (2-5% of GFR).112

defects specific for several groups of amino acids.

These

findings have prompted the search for specific transport
systems responsible for reabsorption of filtered amino acids
It was postulated by Dent and Rose that arginine,
cystine, lysine, and ornithine were reabsorbed by a common
renal transport system.24 Absence of this system in the

homozygote would account for phenotypic cystinuria.

This

hypothesis has been tested experimentally.
Rosenberg et al studied the transport of arginine,
cystine,

lysine,

and ornithine in an experimental model of

male Sprague-Dawley rat kidney cortex slices incubated in
buffer.

Arginine,

cystine,

and lysine were concentrated in

kidney slice cells against chemical concentration gradients
during thirty minute incubation studies.
inhibition between arginine,
demonstrated.

lysine,

Cystine, however,

Mutual competitive

and ornithine were

did not appear to share in

this inhibition ~ although it was concentrated.
experiments suggested that while arginine,

These

lysine,

ornithine shared a common transport mechanism,

and

cystine

uptake v/as by an independent mechanism.
This work was pursued,

by the same research group, with

human renal tissue obtained by open biopsy at the time
of abdominal surgery.38 Kidney cortex slices were incubated
in buffer.

Radioactive amino acids were used to study

transport.

The kidney slices from cystinurics took-up

arginine and lysine,

after thirty minutes of incubation,

to

approximately half the concentration of,controls;. The uptake .of
cystine was, however,

similar to that of controls.

Further support for the separate nature of renal
transport processes for cystine and dibasic amino acids came
from Crawhall's study on renal clearance of amino
acids in nine cystinurics.^ The ratio of cystine clearance

to GFR varied between one and two.

In six out of nine

patients, cystine clearance exceeded GFR.

This suggested

some efflux from the renal tubule cell into the lumen of
the tubule.

The clearances of the dibasic amino acids

were found not to parallel the clearances of cystine.
For example, the ratio of lysine clearance to GFR ranged
from 0.44 to 0.78.

The situation could be explained by

separate carrier mechanisms.
In experiments with slices of human kidney cortex
from two control subjects and two cystinurics, Rosenberg
et al demonstrated two distinct transport systems for
tl

lysine.
A

These systems differed in affinity and capacity.

single transport system for cystine was demonstrated.

We may synthesize the preceeding experimental and clinical
findings by postulating that dibasic amino acid transport
in the human kidney depends on more than a single mechanism.
The model shov/n in Figure C-2 attempts to account for a
system responsible for classical cystinuria as well as
separable cystine and dibasic amino acid transport systems.

Uigurs drZ
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Segal and Smith have provided additional evidence
for distinct transport systems by observing that cystine
uptake by newborn rat kidney cortex in vitro is impaired

and does not read* the normal adult level until fifteen days
of age.^ Lysine uptake by the cortex of the newborn, however,
is comparable to that observed in adults.

These developmental

differences argue against the concept of only one common
transport process for lysine and cystine.

If only one

process existed, it would be difficult to explain the
developmental findings.
The above mentioned experimental evidence would suggest
the theoretical possibility of clinical hyperdibasicaminoaciduria without cystinuria as well as the converse.
Whelan has reported the occurence of elevated excretion of
arginine, lysine, and ornithine without cystinuria in
thirteen of thirty-three kin in a French Canadian
pedigree.

109
7 Oyonagi has reported two siblings with a
rj £

similar biochemical picture.'

The converse situation

was reported by Brodehl: isolated hypercystinuria
was observed in two siblings.

12

The model offered in Figure C-2 remains controversial.
Silbernagl and Deetjen have reported that in microperfusion
experiments, the dibasic amino acids are able to inhibit
cystine reabsorption.

96

This may be explained by at least

one common luminal transport system.

It may also, however,

be explained by Greth's demonstration that cystine can
enter the renal tubule cell via the basal lateral membrane
in rats under conditions where luminal transport does not
4c
occur.
The transport phenomena observed in the rat kidney
cortical slice experiments may have been largely by way of

.

the basal lateral membrane* We may, therefore, have learned
very little about luminal brush border transport by
cortical slice experiments.

88

Silbernagl's microperfusion

study may be closer to the truth - at the brush border.
Segal has attempted to resolve this problem by
studying the uptake of cystine at the membrane locus of
transport.

91

He has used vesicles prepared from rat kidney

brush borders.

In 1977t Segal's group reported that cystine

uptake appears to occur by two distinct transport systems.
A high affinity system is inhibited
amino acids.

by the dibasic

The low affinity system is unaffected by the

dibasic amino acids.

This low affinity system appears to

correspond to that observed by studying amino acid transport
with cortical slices. We may represent these results in Figure C-3.
Figure C-3
lumen of
the renal
tubule

lys
arg
orn
cystine
(high affinity)

interior of
the ceil
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basal lateral
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As the preceeding discussion indicates, the patho¬
physiology of cystinuria is not precisely defined. Addi¬
tional areas of controversy include the explanation of
cystine clearance exceeding GFR in dogs

11

1R

and humans"

(suggesting cystine secretion). The role of cysteine in
the efflux mechanism of the renal tubule cells is not clearly
defined. A ‘cysteine leak into the lumen has been suggested.

.

13

2.

Intestinal
Milne and co-workers studied the effects of oral

doses of lysine and ornithine in homozygous cystinurics
-ft
and in normal control subjects.
The amino acids were less
completely absorbed by the cystinurics and a considerable
fraction appeared in the feces.

In contrast, in normal

subjects absorption was usually complete.
Colonic bacteria converted unabsorbed lysine and
ornithine to cadaverine and putrescine.

These occasionally

occured in sufficient concentration to be detectable in the
urine of cystinurics.

The greater fraction of the intes-

tinally absorbed diamines are converted to piperidine and
pyrrolidine.

Output of these compounds in cystinuric

patients, following lysine or ornithine ingestion, exceeded
that of normals.

Milne's experiments suggested an intes¬

tinal transport defect in cystinuria.

(See Figure C-4)

Figure C-4
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Asatoor, lacey, London, and Milne soon extended their
-r
experiments to include arginine.
An intestinal absorption
defect for arginine was demonstrated in cystinurics.

After

ingestion of arginine, the feces of cystinurics contain
considerable amounts of the bacterial breakdown product
citrulline.

Some of this product appears in the urine.

_ 71>)

QAi

The metabolite pyrrolidine is excreted in greater quantity
by cystinurics than normals in the twenty-four hours following
arginine ingestion.
Detailed investigations by Thier et al defined the
nature of the intestinal defect.jejunal mucosa v/as
obtained via Rubin tube from normal and cystinuric subjects.
Intestinal mucosa from four normal volunteers concentrated
lysine thirteen fold and cystine four and one-half fold.
An initial group of cystinurics failed to concentrate either
of these amino acids significantly. Furthermore, lysine
accumulation was inhibited by arginine or cystine and
cystine uptake was inhibited by lysine. Mucosa from a
subpopulation of cystinurics did absorb cystine - a point
which will be considered later. The transport mechanisms
were found to be energy dependent.
The experimental evidence indicates an intestinal
absorption defect in cystinuria. A single transport system
appears responsible for absorption of cystine and the
dibasic amino acids in the gut. Absence of this system
explains the biochemical findings in the affected individual.
Clinical Aspects
Several individuals have attempted to estimate the
incidence of cystinuria. Lewis0

tested the urines of 10,000

college students with the nitroprusside reaction for cystine.
He found that 1/600 students had a positive reaction. This
estimate is almost certainly too high. The nitroprusside
reaction is positive if urinary cystine is greater than
75mg/liter and, hence, cannot distinguish between
homozygotes and many heterozygotes.

In a 1968

review atricle, Crawhall calculates a homozygous cystinuria
incidence rate of 1/20,000 based on the assumption that the
commonly recessive form of cystinuria is about twice as
frequent as the incompletely recessive form.

Crawhall's

estimate is supported by the figures from the Massachusetts
Metabolic Disorders Screening Program. This newborn
screening program has a cystinuria incidence of 1/17»738
U*T

in a population of 141,903 infants studied.
The first clinical expression of cystinuria usually
occurs in the second or third decades of life.

The disease

may, however, present in infancy or old age. The common
presenting signs are those of urolithiasis: gross haematuria,
abdominal or flank pain, and renal colic with or without
stone passage.

Urinary tract infection may also occur.

Obstructing stones can compromise renal function and
lead to renal failure. Hypertension is associated with
ix

cystinuria in 10/ of cases.

There are no physical stigmata.

Cystinuria occurs equally in both sexes. Males have
been reported to be more severely affected, perhaps due to
lOfe

the greater likelihood of urethral obstruction.

‘

A

recent Mayo Clinic study, however, found that parameters of
morbidity and severity of cystinuria were not significantly
.

.

VL

different m men and women.

Cystine stones constitute about 1 / of all upper
urinary tract stones. The stones are radiopaque due to
the density of the

sulfur region.

'

, About one-half
IO

of stones recovered from cystinurics are pure cystine.
to

Another 45/ to 50/ are cystine mixed with other compounds.

16

One or two percent of recovered stones contain no cystine.
Some physicians, however, believe the incidence of
non-cystine stones in cystinuria is actually much higher
-»a
than two percent.
Cystinuria has been associated with several other
condition. The disease may occur with hyperuricemia* and
.
.
108
uric acid nephrolithiasis. Cystinuria is significantly more
frequent in a population of patients with mental illness or
CVO
retardation than in the general population. It has been
postulated, without experimental confirmation,
ammo acid transport defect involves the brain.

that the
If cystinuria

lowered the IQ of all cystinurics, we could explain the
increase in mental retardation as a shift of the IQ
distribution curve to the left,

(see fig. D-l)

Figure D-1

...
»Q
ystmuria is a heterogeneous disease and it may be that
some genotypes are associated with abnormal IQ distribution
while other genotypes do not affect IQ.

(see fig. D-2)

Figure D-2
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IQ
Since cystinurics do not differ significantly in their

'

intelligence from their normal siblings or intelligence
test norms, the situation suggested by figure D-2 is more
likely.
One might postulate that impaired absorption and
retention of essential amino acids could lead to deficiencies
in the cystinuric individual's growth and development.
Studies looking at the effect of cy^Inuria on final
height are not in agreement. Andrews noted, in 1952,
that in his "experience cystinurics are,

in general,

persons of somewhat less than average stature" and that they
n
"have always been of somewhat slight build." In 1963,
Colliss et al studies a population of cystinurics and found
their mean height to be 2.5cm less than that of normal
subjects. A kayo Clinic study found no significant
difference between the mean height of cystinuric patients
, ,,
xx.
and that of normals.
Diagnosis
Any patient with urolithiasis who has passed renal
stones in childhood, who has many recurrences, or who
has a family history of renal stones deserves a work-up
for cystinuria. The relatives of a diagnosed cystinuric
should be screened in order to identify new and unsuspected
cases.
The suspicion of cystinuria may be confirmed by a simple
and inexpensive microscopic examination of urinary sediment.
The presence of typical, hexagonal "benzene-ring" crystals
is diagnostic. The crystals may be difficult to identify in

18

dilute or alkaline urine.

If glacial acetic acid is used to

lower urine pH to about 4 and the refrigerated urine
allowed to stand overnight, crystals may be found in the
centrifuged sediment.
A simple screening test for cystinuria is the
cyanide-nitroprusside test. Five ml of urine is alkalinized
with 5 drops of NH^OH. Two ml of 5% NaCH is added and the
solution allowed to stand for ten minutes.

If,on addition of

drops of 5c/o Ha Nitroprusside a stable purple-red color
appears the test is read as positive.

The color should be

compared to a sample of normal urine to which cystine has
l©Ce

been added, A positive test may also be seen in acetonuna,
homocystinuria, and a new metabolic disorder characterized by
the excretion of cystine*^—mercaptolactate mixed disulfide.
Diagnostic confirmation depends on the demonstration
of the characteristic pattern of amino acids in the patient's
urine. Paper chromatography or electrophoresis is used to
identify cystine, lysine, arginine, and ornithine in excess
quantities. Column chromatography is used if quantitative
amino acid determination is desired. Homozygotes usually
excrete in excess of 400mg of cystine per day.
On roentgenologic examination, cystine stones are
smooth. They are often multiple and may coalesce to form
staghorn masses. The stones may decrease in size or
disappear if effective therapy is instituted.
tfhen stones are available for examination,

the

diagnosis should not be missed. Cystine stones are

t
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honey yellow to yellow-white in color and may have a
pearly luster. They consist of porous aggregates of
crystals.
Genetics
Harris and his colleagues have made a major contribution
to our understanding of the genetic of cystinuria”!’These
workersi estimating cystine polarographically and dibasic
amino acids by microbiologic assays, found two types of
families of cystinuric individuals.

In one group of

families the parents and children of the cystinuric patient
excreted normal amounts of amino acids. This type of
inheritance was called "recessive cystinuria." In the other
group of families, parents and children of patients were
frequently found who had moderately increased cystine and
lysine excretion with arginine and ornithine excretion being
normal or slightly raised. This situation was called
"incompletely recessive cystinuria." (see fig. F-l)
Figure F-l
The_Harris Model

Q~rO

«
recessive

incompletely recessive

a normal amino acid excretion
^ cystinuria
increased cys, increased lys
The suggestion of genetic heterogeneity in cystinuria
was supported by Thier, et al in their investigation of
amino acid transport by jejunal mucosa in vitro^Ten of

20

twelve stone forming cystinurics had absent uptake of
cystine, lysine, and arginine by jejunal mucosa. Two
patients with typical cystinuria had normal intestinal
transport of cystine with reduced transport of arginine and
lysine. The findings were not associated with differences in
urinary amino acid excretion by homozygotes.
Three1 genetically distinct types of cystinuria were
defined by Rosenberg and co-workers.^ They utilized
in vitro transport studies with gut mucosa, oral loading
studies with cystine, and patterns of urinary excretion
of cystine and dibasic amino acids in heterozygotes to
indicate three biochemically distinct diseases
types I,

(named

II, and III). Homozygotes of all types excrete

excessive urinary cystine and dibasic amino acids. The
distinctions are found in gut transport and heterozygote
expression. Type I, corresponding to Harris'

"recessive"

type, lacks active transport in the gut for disbasic
amino acids. Heterozygotes excrete normal amounts of the
four amino acids in the urine. Type II has impaired
intestinal transport of lysine but cystine transport is
present. Heterozygous type II's excrete definitely
increased amounts of the four amino acids. Homozygous
type III individuals have active intestinal transport of
cystine, lysine, and arginine.
therefore, absorb an oral load.

These individuals can,
Urinary excretion of

the four amino acids is only moderately increased in
heterozygotes for type III. Harris'

"incompletely recessive"

J

cystinuria includes types II and III.
While the proceeding data suggests at least three
mutations resulting in phenotypic cystinuria, it does not
determine if the observed heterogeneity is due to allelic
or nonallelic mutations. Marin's group from Toronto^,
Rosenberg in New Haven80, and Hershka in Israel115 have
described several fascinating families which shed light on‘
this question. Marin's family Cyl (Figure F-2) presented with
a phenotypic cystinuric female II-l. Her brother,

II-4f.

and father, 1-1, were heterozygotes type II. The proband's
mother, 1-2, and sisters, II-2 and II-3, had normal
twenty-four hour urinary amino acid excretions. Proband
II-l had urinary amino acid excretions in amounts midway
betv/een type II heterozygotes and homozygous abnormals.
Her intestinal handling of amino acids v/as between that of
a +/II heterozygote and abnormals I/I or II/II, She
appeared to be a compound heterozygote.
Figure F-2
Family Cvl from Marin et pi6?
®

Type II heterozygote

H3

Type I heterozygote

IB

I/II double heterozygote

Other family studies have revealed II/III and I/III
compound heterozygotes who are phenotypically cystinuric.80
These data are interpreted as evidence for multiple defects

2^

in one allele.
are "I",

If the normal allele is "+" and the mutants

"II", and "III", the genotypes may be described

and identified.

(Table F-3)

Cystinuria type I seems to be the most common form
of the disease.

18 83

’ ^ Interestingly, types II or III are

the more common form in affected Libyan Jews.
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G. Treatment
The goals of therapy are:

(1) To prevent stone

formation if it has not yet occurred,

(2) To stabilize and

hopefully dissolve existing stones. Fulfillment of these
goals has been pursued by attempts to decrease production
of cystine and/or increase the solubility of the amino acid
in the urine. Each of the major therapeutic maneuvers will
be explained and evaluated in turn.
(1) Dietary Therapy
Cystine is produced from the essential amino acid
methionine by the transsulfuration metabolic pathway. Low
methionine or low protein diets have been proposed to lower
the amount of cystine which comes to urinary excretion. Dent

and Senior reported in 1955 that a low protein diet decreased
cystine excretion m their patients. Hershka and co-workers
have reported that a chronic low methionine diet, rigorously
observed for ten years, and increased fluid intake produced
a biochemical "cure" of their patient's cystinuria. Lotz,
et al note that a patient on a relatively constant low’
methionine diet reduced his twenty-four hour urinary cystine
excretion by nearly 50%. Zinneman and Jones, on the other
hand, found that neither methionine restriction or*
methionine loading appreciably influenced the urinary
excretion of cystine.
A low protein diet is difficult

to adhere to and

the wisdom of protein-restriction for pediatric cases is
questionable. The cystinuria patient should avoid excessive

I
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protein intake. However, a formal low methionine diet is
probably not warranted.
(2) Fluids
Within the usual range of urinary pH, about 300mg of
lb

cystine will be dissolved in one liter of urine. The
principal task of fluid therapy is to solubilize the
cystine in a sufficient volume of urine to avoid precipitation.
Since many cystinurics excrete up to lg of cystine per day,
they will require 1 liter/300 mg X 1 gram/day = 3^°0ml of
urine flow per day as a minimum (2-3ml/min). To attain this,.'
Dent's group advises patients to consume 600ml (about one
2*5

pint) of liquid every four hours. This should be regarded
as a minimum. The patient is free to select tap-water,
tea, beer - whatever he/she wishes.

Since urine is

concentrated at night, a large drink is taken before
retiring.

The patient should arise at least once in the

middle of the night to void and drink again.
Reports of disease stabilization and stone dissolution
1*5

from high fluid therapy emphasize the value of this method.
Fluids remain the first line of therapy for cystinuria.
The cystinuric individual should be made to understand that
"for him/her, water is to the cystinuric as insulin is to
81
the diabetic," The patient should be encouraged to drink
at each visit to the physician. The urine should always be
pale in color - never dark yellow. Some patients follow
their own urine specific gravities - taking care to
maintain it below 1.010. Fluid intake must be increased

in warm climates and during times of vigorous physical
activity.
Children present particularly difficult
problems. Patience and care

therapeutic

oh the part of parents,

sios,

and the physician will be necessary to convince the child
to drink adequate volumes. The battle may be lost if the
issue is pressed too strongly too soon.

The child must be

enlisted in his/her own care. Vigorous childhood activity,
which increases fluid losses, must be accompanied by adequate
hydration.
(3) Alkalinization
The solubility of cystine begins to increase rapidly
at a urinary pH above ?.5*

(fig* G-l)

Figure G-l
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therefore, been thought to be of value

in stone prevention and dissolution. Urinary alkalinization
is achieved by day-time ingestion of bicarbonate or citrate
preparations (ie Sodium Bicarbonate, Polycitra).

Since the

value of alkalinization is not realized until a high
urine pH is reached, doses of 30g/day of NaHCO^ may be
required. A bedtime dose of acetazolamide

(250mg to

500mg) is used to achieve nightime alkalinization. Patients

may monitor their own therapy with commercial dipstick
pH tests,
Alkalinization is not without danger.

Calcium

phosphate tends to precipitate in an alkaline urine,

thus

presidposing to nephrocalcinosis or the deposition of
calcium salts on an existing cystine stone.

In addition,

metabolic alkalosis may be produced. Finally, there may be
a contradindication to the obligate cation load for some
patients. Because of side-effects and the difficulty in
maintaining sufficiently alkaline urine, clinicians differ
on the importance of urinary alkalinization in cystinuria,
(4) Penicillamine
Disulfides undergo exchange reactions with thiols and
other disulfides. These reactions may be simply represented
by the equations
R-S-S-R + R1-S-H ^ R-S-S-R1 + R-S-H
R-S-S-R + R1-S-S-R1

2R-S-S-R1

The mixed disulfide RSSR-^ has different properties than
the symmetrical dissulfide RSSR. Preliminary experiments
showed that cystine which readily crystallized from the urine
of cystinurics could not be crystallized from the same urines
at pH 7.2 after the addition of D-penicillamine. The
penicillamine-cysteine disulfide is fifty times more soluble
(.U

than cystine,

(see fig. G-2)

Figure G-2
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The solubility difference is exploited in therapy for
cystinuria.
Crawhall,

Scowen,

and Watts fed D-penicillamine to

two cystinuric patients.

They were able to demonstrate that

the excretion of cystine was abolished or reduced according
to the dose of penicillamine administered.

During penicillamine

administration two new substances appeared in the urine.
They proved to be penicillamine-cysteine disulfide and
penicillamine-penicillamine disulfide.
Clinical experience has shown that 1 to 2g/day of
penicillamine in the adult,

given in four divided doses,

can reduce urinary cystine to 100-150mg/day.
the range of stone formation.

This is below

Stabilization of stone

disease and stone dissolution may be produced by penillamine
administration.

The clinical efficacy of the drug has been

reported in adults and children.

Therapy may be monitored

by periodic quantitative amino acid analysis of the urine.
A surprising observation,
is that total cystine excretion

in the patients with cystinuria,
(measured as the total of

cysteinepresent as cystine plus that present as
penicillamine -SS- Cysteine) consistently decreased with
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increasing doses of penicillamine.

In normals,

the total

amount of half-cystine excreted was increased by penicillamine
There is no satisfactory explanation for this finding.'0**
In addition to cystinuria,
Wilson s Disease,

penicillamine is used in

lead poisoning,

and rheumatoid arthritis.

A substantial literature is accumulating on the side-effects
of the drug,

ihese toxic effects may be considered under

the headings of (a)
changes,
toxicity,
topathy,

sensitivity reactions,

(b) haematologic

(c) abnormalities of taste and smell,
(e)
(g)

formation of abnormal antibodies,
connective tissue changes,

and

(d) nephro¬
(f)

derma-

(h) other.

(a) One-third to one-half of patients receiving
penicillamine suffer from maculopapular skin erruptions,
fever,

lymphadenopathy, pruritus,

and arthropathy within

one to ten days of receiving the drug.
disappear on withdrawal Of the drug.

These reactions

Reinstitution may

be attempted with a "desensitizing" dose of lOmg/day with
a gradual increase to full dose.

Others reinstitute under

coverage of prednisone.
(b) Leukopenia,

thrombocytopenia,

thrombocytosis,

and thrombohemolytic thrombocytopenic purpura* have been
associated with penicillamine.

Therapy must be monitored

with frequent platlet and white cell counts.
are frequently counted by machine.

Thrombocytes

Because of clumping a

falsely low count may be recorded and a visual check should be
made before discontinuing therapy.**'

(.U

(c) Hypogeusia is not infrequently seen.

It may be

reversed by copper administration and is rarely seen in
the therapy for Wilson's Disease,^
pyridoxine antagonist

Penicillamine is a

*and taste abnormalities may

generally be reversed by a

50mg/day supplement of vitamin

V
(d) Up to one-third of patients suffer from
penicillamine induced proteinuria. ^9»86,l20

rp^s ^as

been reported to progress to frank nephrotic syndrome.1
The renal biopsy shows focal glomerulitis resembling changes
reported in iramunologically induced experimental nephritis.*
The drug should be stopped and the patient followed with
quantitative urine proteins.

Spontaneous resolution is

to be expected,
(e) Anti-nuclear and anti-cytoplasmic antibodies
have been found in the sera of patients receiving
penicillamine.

Cutaneous lupus has been reported to

be induced by penicillamine.6 Fatal pulmonary haemorrhages
and rapidly progressive glomerulonephritis occurred in
three patients with Wilson's Disease who had been treated
with penicillamine for two to three and one-half years.
The clinical and pathologic abnormalities were similar to
those of Goodpasture's Syndrome.117 Myasthenia has also
been reported with use of the drug,29
(f) Patients with Wilson's Disease have been reported
to suffer from extravasation of blood into the skin particularly around joints.102 In addition,

a drying and

scaling of the facial skin is associated with the drug.102

(g) Penicillamine produces an accumulation of
poorly cross-linked^,

soluble collagen*® in the skin.

This phenomena appears to be dose related.

The drug

probably should not be administered in the pre- and
post- operative periods.
(h) Nausea, vomiting, malaise,

and midepigastric

pain have been associated with initiation of
D-peniciilamine therapy.
As one might expect,

the toxicities of

penicillamine make one hesitant to prescribe the drug m spite of its therapeutic efficacy.
accepted indications are:

The two generally

inability to control stone

formation on more conservative therapy,

and repeated

surgery or a nephrectomy while on conservative therapy.
The drug should be initiated at low dose with gradual
increase to full dosage.

Monitoring with a complete

blood count and dipstick for urine protein are
mandatory.

H.

Progress in Therapy
Investigators have tried new drugs in the attempt to
improve therapy for cystinuria. This work is given impetus
by the difficulty patients have in following prescribed
regimens of fluids and alkalinization, The well-known toxic
effects of penicillamine have also prompted the search for
new drugs.
Mulvaney, et al^ have reported their experience with
six cases of cystinuria treated with acetylcysteine.

It

has been speculated that this oral agent causes cysteine
to be converted to cystine disulfide, which is approximately
fifty times more soluble than cystine. The authors report
some success in reduction in stone size and number,
and control of symptoms.
German researchers have reported on attempts to
manage cystinuria with mercaptoproprionyl glycine.

The

mechanism of action of this oral agent is the thiol
disulfide exchange reaction. An early clinical report
claimed stabilization or dissolution of stones in seven
of nine patients.

ll 6

One drug-associated rash was seen.

Nine additional patients have recently been reported to be
in excellent control with the drug.^2
A curiosity is the recently reported first "surgical
'cure' of the disease." A compound heterozygote I/III
received a renal transplant for "end-stage kidney failure."
Pretransplant dibasic amino acid excretion rates were

clearly abnormal. Excretory rates for the
measured from samples collected six week

•
min°

WOnths posttransplant, are with!
'
^
transplant is not of c
th« normal limits. 58
X* Of Course, offered
therapeutic intervention tor^ut^ “ ^
routine cystinuria.

II.

THE MANAGEMENT OF CYSTINURIA:

PRESENTATION OF DATA

FROM A CLINICAL STUDY

A.

Goals of the Study
A study was undertaken on the clinical characteristics
of cystmuria.

There were seven major goals of this study?

1)

To identify a population of phenotypic cystinurics

2)

To record the major demographic characteristics
of this population

3)

To document the most common presenting symptoms
To establish the average age at the onset of
symptoms and the average age of diagnosis

5)

To compare the common modalities of therapy for
cystinuria to.evaluate the most effective mode(s)

6)

lo study and record the most frequently cited
indications for the initiation of penicillamine
therapy

?)

To record the drug reactions due to penicillamine
and demonstrate:
a)

The frequency of drug reactions

b)

The best manner in which to avoid drug
reactions

c)

The best manner(s) in which to treat drug
reactions once they occur

d)

The frequency with which drug reactions
prevent the use of penicillamine in therapy

The principal objectives of this thesis were the ful¬
fillment of goals 5),
was fulfilled.

6), and ?).

Each of the seven goals

In the six sections which follow, the results

of each study are presented.
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B.

Identification of the Population
1.

Goal
To identify a population of phenotypic cystinurics

2.

Methods
To locate as complete and as representative a popula¬

tion of cystinurics as possible, multiple channels for
patient location were used.

These efforts were carried

out within the constraints of:

the limited amount of time

allowable for a medical student's thesis, the fact of
limited financial resources, and the necessity of all
work being conducted by a single researcher.
Initial inquiries were sent to the medical records
librarians of nine hospitals:

The Children’s Hospital of

Philadelphia, The Clinical Center of the National Insti¬
tutes of Health, Coney Island Hospital, The Hospital of
the University of Pennsylvania, Johns Hopkins Hospital,
Massachusetts General Hospital, The University of Maryland
Hospital, The West Haven (Connecticut) Veteran's Administra¬
tion Hospital, and Yale-New Haven Hospital.

Cooperation

was readily obtained from medical records librarians at
Coney Island, West Haven VA, and Yale-New Haven Hospitals.
Through the cooperation of local physicians, the regulations
governing outside researchers were modified, and access to
records were obtained at Children's Hospital of Philadelphia,
Hospital of the University of Pennsylvania, and Massachu¬
setts General Hospital.

Approval to examine records at the

National Institutes of Health came too late to allow use

‘

of these records.

Access to records could not be obtained

at Johns Hopkins Hospital or University of Maryland Hospital.
In addition to the aforementioned hospitals,
tance of seven physicians were solicited.

the assis¬

These physicians

L. Beck, MD (Philadelphia), E. Prien, Jr., MD

were?

(Boston), H. Rosen, MD (Brooklyn), L.E. Rosenberg, MD
(New Haven), S. Segal, MD (Philadelphia), and M. Yudkoff,
MD (Philadelphia).

All physicians, who were asked to help

locate patients, immediately agreed to do so.
The method used to locate patient records varied with
each source.

At the West Haven VA and Yale-New Haven

Hospitals, the International Classification of Disease code
number for cystinuria, 270.1, was used to locate every patient
witn that diagnosis discharged over the entire period for
which records were saved.

Then the files of the Yale Genetics

Clinic were examined to locate any ambulatory patients missed
by searching for discharge diagnoses.

Five New Haven physi¬

cians allowed access to office records to complete the search
for patients:

A. Baskin, MD, B. Lytton, MD, L. Rosenberg,

MD, S. Thier, MD, and R. Weiss, MD.
Physicians at Coney Island Hospital and Hospital of the
University of Pennsylvania provided lists, from memory, of
cystinuria patients.

The appropriate records were examined.

Physicians at Children's Hospital of Philadelphia similarly
provided a list from memory but also allowed a search of the
ambulatory clinic file - and thus provided several more
patients.

p

•' t
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In Boston, Dr. E.L. Prien, Jr. provided invaluable
assistance by surveying members of four departments of
the Massachusetts General Hospital for lists of all cystinuria patients seen at that institution.

Ten patients

were located at this hospital.
For each patient located, medical records were examined
by this writer.

These included hospital charts, clinic

charts, office records, and correspondence files.

When¬

ever possible the records were personally examined.

Trips

were made from New Haven to Boston, Brooklyn, and Phila¬
delphia to review charts.

When possible, photocopies of

records were obtained from community hospitals where members
of the cystinuric population had received a portion of their
care.

If complete records were not available, summaries

were used.
Each patient record was analyzed to determine if
the patient met the diagnostic criteria of phenotypic
cystinuria.
a)

These criteria included:

The finding of a pure cystine, cystine and cal¬
cium oxalate, cystine and calcium phosphate, or
cystine and magnesium ammonium phosphate stone
in the course of urinary tract lithotomy surgery.

b)

Passage of cystine gravel or a cystine stone from
the urinary tract.

c)

Finding the hexagonal, flat crystals of cystine in
a concentrated urine specimen.
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d)

Urinary cystine excretion greater than or equal
to 400 mg/day or 250 mg/g of creatinine.

e)

Paper chromotographic or electrophorectic technique
showing excessive excretion of cystine, lysine,
arginine, and ornithine.

f)

A positive nitroprusside test.

A patient was accepted into the study if he/she met
at least one of the criteria.
The first calculation made, after a patient was
accepted into the study group, was the number of years of
follow-up available per patient.
in two ways.

These numbers are derived

The first method involves subtracting the date

of the first note in the records from the date of the last to
give the number of months of "direct documentation."

The sec¬

ond method calls for the subtraction of the birth date from
the date of the last note in the record.

This second method

is of value in giving an indication of approximately how
many years of the natural history of cystinuria we observe.
This assumes, of course, that an adequate medical history
is recorded to cover the years prior to the creation of the
record.
3.

Results
Medical records on fifty six individuals who carried

the diagnosis of cystinuria were eventually obtained.
complete listing of all sources of data may be found in
table B-l.

A
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Table B-l
The Sources of Data on Fifty-Six Cystinuria Patients
The number following the name of the source is the total
number of patients to whom this source contributed data.
The sources are listed alphabetically.
A. Baskin, MD - Office Record (1)
New Haven, Connecticut
L. Beck, MD - Office Record (2)
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Charles Choate Memorial Hospital (1)
Woburn, Massachusetts
Children's Hospital of Philadelphia (2)
Philadelphia, Pennsylvania
Clinica de Nuestra Senora de la Conception (1)
Ciudad Universitario
Madrid, Spain
C. H. Coggins, MD - Office Record (2)
Massachusetts General Hospital
Boston, Massachusetts
Coney Island Hospital (2)
Brooklyn, New York
D. Cornfeld, MD- Office Record (1)
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Danbury Hospital (1)
Danbury, Connecticut
Genetics Clinic (13)
Yale-New Haven Hospital
New Haven, Connecticut
Hamilton, MD - Office Record (1)
Danbury, Connecticut
J. Herrin, MD - Office Record (3)
Massachusetts General Hospital
Boston, Massachusetts

Jack Dempsey Hospital (1)
Farmington, Connecticut
The Jewish Hospital and Medical Center (1)
Brooklyn, Hew York
S. Kramer, MD - Office Record (2)
Massachusetts General Hospital
Boston, Massachusetts
Laurence and Memorial Hospitals
Hew London, Connecticut

(1)

Long Island Jewish-Hillside Medical Center (1)
New Hyde Lark, Hew York
B. Lytton, MD - Office Record (1)
New Haven, Connecticut
Massachusetts General Hospital
Boston, Massachusetts
Mount Sinai Hospital
New York, Hew York

(9)

(1)

Park City Hospital (1)
Bridgeport, Connecticut
E. Prien, Jr., MD - Office Record (2)
Massachusetts General Hospital
Boston, Massachusetts
St. Joseph's Hospital (1)
Carbondale, Pennsylvania
St. Joseph's Hospital (1)
Stamford, Connecticut
S. Segal, MD - Office Record (1)
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
S.O. Thier, MD - Office Record
Yale-New Haven Hospital
New Haven, Connecticut

(6)

R. Weiss, MD - Office Record (1)
Yale-New Haven Hospital
New Haven, Connecticut
West Haven Veteran’s Administration Hospital (2)
West Haven, Connecticut

Yale Health Plan (1)
New Haven, Connecticut
Yale-New Haven Hospital (29)
New Haven, Connecticut
Yudkoff, MD - Office Record (6)
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
The names of the individual patients will not be
disclosed.
Care was taken to record the diagnostic criteria
for phenotypic cystinuria fulfilled by each patient.
Arbitrarily, the time period up to three months following
the initial positive diagnostic test was called
"initial" work-up. The time following "initial"
work-up is called "subsequent" work-up. Table B-2
shows how well the population met the diagnostic criteria
"initially" and "subsequently".

In addition, we show

the number of patients who met only one of the
diagnostic criteria.

Table B-2
How the Diagnosis Was Made

Diagnostic Criteria

Met ir1 0-3
Moniths
No.

Met After 3
Months

Patients For
Whom This
Was The Only
Criterion

%

No.

%

No.

455s

32

57 $

3

5°/o

_

a) The finding of a
pure cystine, cys¬
tine and calcium
phosphate, or cys¬
tine and magnesium
ammonium phosphate
stone in the course
of urinary tract
lithotomy surgery

25

b) Passage of cystine .
gravel or stone
from the urinary
tract

13

23 %

19

34

1

2fo

c) Finding cystine
crystals in a
urine specimen

13

2y/o

17

30

1

2 c/o

d) Urinary cystine
greater than or
equal to 400 mg/day
or 250 mg/g of
creatinine

20

%%

33

59%

2

4%

12
e) Paper chromatogra¬
phic electrophoretic
technique showing
excessive excretion
of cystine, lysine,
arginine, and orni¬
thine

21 %

23

41 fo

0

0/

20

36 %

29

52c/o

1

C

f) Positive nitroprusside test

y>°\ vcnL

O cl
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Table B-3 shows the results of the calculation of
number of years of available data.

This calculation is

based on fifty-two of the fifty-six patients for whom
data on therapy was available.

Table B-3
The Number of Years of Data Obtained on the Patients
Number of years determined by subtracting the first note
in the chart from the last note:
mean

7 years 3 months

range 1 month - 48 years 8 months
Number of years determined by subtracting the birth date
from the last note in the chart:
mean
range

4.

32 years 10 months

1 month - 58 years 5 months

Discussion

Several writers have previously identified populations
uo

of cystinurics.

Kretschmer

, in a 1916 review, was able

to find reports of only 107 cases of cystine calculi in
a period of more than a century since Wollaston's original
NO
ul
report of 1810.

In 1931*

lewis

summarized 71 cases.

In an attempt to establish accurate incidence figures
for cystinuria, Lewis undertook the systematic chemical
examination of more than 10,000 college students for the
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presence of cystine.

In 1932 he reported the identification

of 18 individuals as "definitely cystinuric".

This sug¬

gested that cystinuria uncomplicated by calculi occured
more frequently than usually believed.
Larger series of cystinurics have been identified
in recent years.

K> strom and Hambraeus have reported

extensively on "98 cases of homozygous cystinuria" collected over a 92 year period.

MacDonald and Fellers

collected sixteen cases for their 1966 report on the
efficacy of penicillamine in cystinuria.

In 1968,
140

Frimpter reviewed the experience at New York Hospital.
An extensive clinical study on eight-nine patients,
similar in several of its aims to our work, was recently
T.X

reported by a Mayo Clinic group.
For our study, fifty-six patients were located.

This

represents, as far as can be determined, the largest pop¬
ulation of cystinurics compiled from multiple medical
centers for the purpose of studying the therapy of cys¬
tinuria.

Table B-2 shows the evidence that we are,

fact, dealing with phenotypic cystinurics.

in

It is reassuring

to note that only eight of the fifty-six patients

(14%) were

admitted to the study group by fulfilling only one of the
diagnostic criteria.
The reader is reminded that no claim is made to have
compiled a population of "homozygous" cystinurics.

It

is now known that mixed heterozygotes can present a pheno¬
typic picture similar to a homozygote.

The claim of having

compiled a group of homozygotes is unjustified in the
absence of detailed biochemical studies and pedigrees.
A mean of 7 years 3 months of direct chart data was
obtained per patient (Table B-3).

This compares favor¬

ably with the Mayo Clinic's mean "follow-up" on their
ti

population of 4 years 4.8 months.

Demographic Characteristics of the Population
1.

Goal
To record the major demographic characteristics of

the population of cystinurics.
2.

Methods
Data on sex, race, religion, and marital status was

recorded based on information obtained from medical
records.

For those patients who came to surgery, blood

typing was done.

Blood type distribution for this sub¬

population of cystinurics was recorded.
3.

Results
It was possible to determine the race of forty-seven

patients.
Table C-l
Race_Patients°J>
Caucasian
Negro

44

94^

3

6%

The sex of all fifty-six patients was known.

Table C-2
—_

Patients

%

tfaie

29

52%

Female '

27

48^

Data on religion was obtained for thirty patients.
Ihirteen were Roman Catholic (43%), nine were Protestant
(30%), and eight were Jewish {27%).
Oi the fifty patients for whom marital status was
recorded, twenty-six were married {%2C%) and an additional
four became married during the time period recorded in
the chart (8%).

Nineteen were single (38^).

One was

married and divorced (2%).
Blood types of sixteen patients were known.
Table C-3
—Blood Types_Patients

%

A+

4

25 %

B+

4

25 %

B“

0+

16%
7

44 %

Discussion
Ninety-four percent of our patients are Caucasian
and six percent are Negro.
of cystinuria in Negroes.

There are occasional reports
Fleming, et af

have given a

detailed account of gastrointestinal malabsorption associated
with cystinuria in a fourteen year old Negro boy.

Cystinuria

is also reported in Orientals.

The population recently

reported from the Mayo Clinic is entirely Caucasoid.
One would expect that there would be a random sex
distribution in a non-sex linked recessive disorder.

This

is supponed by the male/female = ^>2fo/kQ0/o breakdown.

The

xinding of an appropriate sex distribution argues against
gross bias in patient identification.
of MacDonald’s patients4**

Fifty-six percent

and Dahlberg's patients

were males.
The religious preferences of our population are quite
different from national figures.

Approximately 130

million Americans are listed as church members.

Of this

number, 54^ are Protestant, 38# Roman Catholic, and 3^
V*S-

are Jewish.

The unusually high number of Catholics and

Jews in our population is likely a function of the popula¬
tion being drawn from northeastern urban centers.
The most common blood types in Caucasian North
Americans are 0 (460) and A (42%)?

The blood type

distribution of Table C-3 suggests the normal distribution.
However, our numbers are quite small.
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The Clinical Presentation of Cystinuria
1. Goal
To document the most common presenting symptoms of
cystinuria and present this data in a manner useful to the
clinician
2. Methods
Traditionally, the terms "chief complaint" or
"presenting symptom" have been used to describe the first clue
to the detection of a disease.

For the clinician interested in

cystinuria, these terms are probably inadequate. A significant
percentage of newly diagnosed cystinurics have no complaints.
A more appropriate term, used by Feinstein, is "iatrotropic
stimulus": the symptom or event that provokes a patient to

n

see a doctor.

The data on the most common iatrotropic stimuli is
presented in two ways. First, a table presenting each item
singly is shown.

(Table D-l) Since many patients have more than

one impetus to seek medical attention, the number of stimuli
exceed the number of patients.
The second table

(Table D-2) groups the stimuli into the

common patterns reported by patients. The total number of
stimuli groups, therefore, equals the number of patients.
3. Results
Table D-l presents the individual iatrotropic stimuli.

■

Table D-l

% Of
Iatrotropic Stimuli_Number

Patient s

28

50#

Haematuria

11

20 %

Having an affected family
member prompted the patient
to come for screening

9

16#

Spontaneous stone passage

7

13#

Urinary tract infection

5

9#

Back pain

3

5#

Anuria

2

4$

Nervousness and dyspepsia

1

2#

Routine urinalysis discovery

1

2#

Screening during a diagnostic
work-up for mental retardation

1

2#

Unknown

1

\£.

CM

Renal colic

I

50

In Table D-2 the association between stimuli are shown.
Table D-2

latr^trooic Stimuli

Number

Plat lints

19

34 %

9

16 %

6

11 %

Urinary tract infection

4

7 7°

Spontaneous stone passage

3

o/
J*5 °/o

2

4 %

2

4 %

Renal colic
Having an affected family
member prompted the patient
to come for screening
Haematuria and renal colic

Anuria
Renal colic and spontaneous
stone passage
Back pain

1

2

Back pain and renal colic

1

2

%

Back pain and haematuria and
spontaneous stone

1

2

%

Haematuria and spontaneous stone

1

2

%

Haematuria and urinary tract
infection

1

2

%

Nervousness and dyspepsia

1

2

°/°

Routine urinalysis discovery

1

2

oi
7°

Screening during a diagnostic
work-up for mental retardation

1

2

%

Unknown

1

2 %

.
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4.

Discussion
The most common iatratropic stimuli for the cystinuric

are renal colic, haematuria, and having an affected family
member.

Comparison of Tables D-l and D-2 shows that renal

colic often occurs alone while haematuria is rarely a
solitary complaint.

A significant number of cystinurics

are first seen because of an affected family member.
Case reports, of cystinuria commonly cite renal colic,
haematuria, and stone passage as "presenting complaints".
Our findings confirm this experience.
2

In MacDonald's series of twelve patients
(5W

"presented because of calculi, two

, seven

(17%) were

traced through their siblings, and two were traced by
routine screening of urine samples" undertaken for reasons
other than cystinuria.

The last patient presented with a

suspected urinary-tract infection.
E.

The Average Age at Onset of Symptoms and the Average Age
of Diagnosis
1.

Goals
To establish the average age at the onset of symptoms

and the average age at time of diagnosis; To study the
value of the family history as part of the original diagnostic
work-up.

2.

Methods
The vast majority of medical histories identify a

first event suggestive of urinary tract pathology.

In

most cases this event was coincident with the iatrotropic
stimulus.

The date of occurence of the first symptom,

the nearest month, was recorded.

to

The patients age at the

onset of the first symptom was calculated.

From this data

the mean and median ages at onset of symptoms were derived.
As demonstrated in Tables D-l and D-2,

sixteen per¬

cent of patients first came to medical attention because
of urinary screening following the discovery of an affected
family member.

These patients were assymptomatic at the

time of initial presentation.

Since we are interested in

determining the average age at the onset of symptoms,

these

assymptomatic presentations are not included in the cal¬
culations for Tables E-l and E-2.
The date on which at least one of the diagnostic
criteria for phenotypic cystinuria, as listed in section
II-B, was fulfilled is considered the "date of diagnosis".
The patient s age at diagnosis was determined and an average
age at diagnosis was calculated for the population.

/

Family histories, taken at the time of initial
presentation, were studied. From these histories cumulative
figures v/ere prepared on the precent of patients with family
histories positive for cystinuria or other renal disease.
These figures were compiled in order to analyze the value of
the family history in the differential diagnosis of stone
disease. Only the initial history was studied - not the
detailed pedigree typically done by Human Genetics Fellows
after the diagnosis was known.

Patients who initially presented

because of an affected family member were excluded from this
calculation since they invariably had positive family
histories.
3. Results
Table H-l

Age At Onset Of Symptoms
Mean_Median
Male

17.3 years 18 years

Female

19.6

years 19 years

Table

E~2

Me At Time Of Diagnosis
Mean_
Male

years

20 years

22.4 years

23 years

22.3

Female

Table

Median

E-l

Family History, At Initial Presentation,

of Patients

Presenting wi~th Slone Disease
History Positive For:
Cystinuria
Unknown Renal Stone
Disease
Unknown Renal Disease
History negative for renal
disease
History Unknown

Humber of
Patients

%

14

29%

6

1

26

2

12%
2%
53%
k%

Discussion
Rosenberg and Scriver report that the initial
symptoms of cystine lithiasis

"are most common during

the third and fourth decades."86 Thier and Segal
advise that

the second and third decades appear to be

the peak times for the expression of cystinuria.
median age at onset in the 197? Mayo Clinic series was
19 years.

Our data confirm an average age at onset

in the late teens.
There is a three to five year discrepancy between
average age at onset of symptoms and age at time of
diagnosis.

Unfortunately, many cystinuric individuals

go undiagnosed or are misdiagnosed for several years
after initial symptoms.

Cystinuria should be included

in the differential diagnosis of stone formation in
the younger age groups.
In an autosomal recessive disease,

one would

expect the disease to occur in only a single generation.
These disorders are more frequently seen in the products
of consanguinous marriages.
therefore,

It is not suprising,

to find a minority of patients with positive

family histories for cystinuria.
however,

It is equally clear,

that a negative family history does not exclude

the disease.

Fifty percent of the Mayo Clinic's patients

.
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"recalled a family history of colic or urolithiasis in
in.
first generation or second generation relatives." Forty-three
percent of our patients had a family history positive for
cystinuria or other renal disease.
The detailed pedigrees done on cystinuric patients by
geneticists may provide

clinically useful information. A

carefully taken pedigree should be part of the work-up and
counseling of these patients.
,

A Comparison of Modes of Therapy
1. Goal
To compare the common modalities of therapy for cystinuria
to evaluate the most effective mode(s)
2, Methods
Cystinuria is primarily treated with vigorous fluid
ingestion. Fluid ingestion, however,

is frequently combined

with urinary alkalinizing agents and/or penicillamine.
four most commonly used treatment programs are:
alone;

(2) fluids and alkali;

The

(1) fluids

(3) fluids and penicillamine;

(4) fluids, alkali, and penicillamine. We may define these
terms:
"Fluids" means encouraging the patient to consume
several liters of fluid per day (the absolute
amount varied by clinician) in order to maintain
a high volume of urinary output.
"Alkali" includes the use of bicarbonate, citrate, or
acetazolamide to alkalinize the urine.
"Penicillamine" is the chelating agent D-penicillamine.
The measurement of the efficacy of these treatments is
a difficult task. There is no reasonable way to quantitate

■
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whether any one modality is more effective at making people
"feel better". What one can quantitate are indirect measures
of the ability of a therapy to aid the patient.

In the case

of cystinuria, six such measurements, or indices, have been
selected. The indices are: rate of urinary tract lithotomy
surgery, rate of cystoscopy, rate of occurrence of renal
colic, rate of occurrence of urinary tract infections,
episodes of spontaneous stone passage, and roentgenographic
evidence of change in stone size or number.

Each of the

indices, save for roentgenographic evidence of stone change,
will be expressed as a rate. The indices are defined as
follows:
"Urinary tract lithotomy surgery" includes pelviolithotomy,
nephrolithomy, ureterolithotomy, nephrectomy
secondary to stone disease, and cystolithotomy.
"Cystoscopy" is examination of the urinary tract by
cystoscope.
"Renal Colic" is characteristically visceral pain
with fluctuations corresponding to smooth muscle
peristalsis produced by thrombosis or dissection
of the renal artery, renal infarction, intrarenal
mass lesions, the passage of a stone within the
collecting system, or thrombosis of the renal
vein.
We shall restrict ourselves to those
incidents of renal colic associated with a
stone. The association may be demonstrated by
roentgenographic studies, concurrent with the
episode of colic, demonstrating the stone;
by passage of a stone; or by finding a stone
at surgery.
"Urinary tract infection" is manifested by dysuria
(discomfort, pain, burning, stinging on
urination), urgency, and frequency. Cystitis,
on the other hand, produces suprapubic pain and
tenderness. Bacteriuria is the hallmark of
urinary tract infections. In this study no urinary
tract infection will be counted as such unless
there is evidence of bacteriuria. One or more of
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the following constitute acceptable evidence:
(1) Growth of 105 or more bacteria per ml
of urine from a clean voided midstream
specimen
(2) Growth of 10 or more bacteria per ml of
urine from a suprapubic percutaneous
aspiration of urine
(3) Readily finding bacteria in a drop or loop
of freshly voided uncentrifuged urine
^
examined with an oil immersion objective
"Spontaneous stone passage" is an episode of passing
a "stone" or "gravel" per urethra and observed
by the patient, nurse, physician, or family
member.
Roentgenographic assessment of stone disease was done
based on criteria developed by Smith.
(1) Fetabolically active urolithiasis is defined
by roentgenographic studies, over time,
f
showing either evidence of stone growth or
evidence of increase in stone number.
(2) Metabolically stable urolithiasis is
defined by roentgenographic studies, over
time, showing no change in stone size or
number.
(3) Improving stone disease is defined by
roentgenographic studies, over time, showing
decrease in stone size and/or.number.
(4) Indeterminate activity is said to exist
when either: a) Films are not available or
are inadequate for evaluation of stone
disease, b) Surgery or stone passage has
occurred between roentgenographic studies
changing stone size or number.
The denominator for the computation of the rates of
occurrence of the above-defined

numerators will be the

"patient-year of observation". The number of persons observed
and the duration of observation of each person on each therapy
has been considered. For example, two persons on fluid therapy
alone, for eighteen months each, constitute three patient-years
13

of observation of fluid therapy. The patient-year is particularly
useful in the study of cystinuria. One must remember,
however, that the patient-year concept is limited by the

/

'
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inherent assumption that the risk being measured remains
constant for any subject during the time of observation.
Life tables are not' appropriate for studying the therapy
of cystinuria. The cystinuric population’s variability of
» sex, and periods of individuals being on therapy makes
computation of actuarial life tables quite difficult.

In

particular, the typical cystinuric patient changes therapy so
often that it would be impossible to maintain sufficient patients
in the study group for life table analysis.
Having defined numerators

(surgery, colic, etc.) and

denominators (patient-years) for the indices which will be
used, we must answer the question;Which patients constitute
the appropriate reference group? It is inappropriate to
simply compare cystinuric patients on fluids alone to those,
say, on fluids plus penicillamine. One suspects that those
patients who have alkali and/or penicillamine added

to their

fluid therapy have, for the most part, clinically more severe
disease than those on fluids alone. The absolute number of
therapeutic interventions increase as a function of the
inability of more conservative measures to control disease.
Data supporting this particular argu~'ment is presented in
the "Results" section as Table F-l.
If we freely compared, say, penicillamine-treated to
nonpenicillamine-treated patients we would be comparing
"relatively sick" patients to "relatively well" patients.
This would certainly be unreasonable. A method must be found
to select-out the patient-years of "relatively sick" cystinurics
and compare treatment modalities within this group.

■
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There are two ways to select out the "sicker" cystinuric
patients.

One may use either "symptomatic" criteria or

"treatment" criteria.

"Symptomatic" criteria arise from

patient symptoms or objective laboratory and x-ray data.
Examples of such criteria are:
- only study patients excreting more than an
arbitrary number of milligrams of cystine per
24 hours
- study those patients who have x-ray evidence of
stones greater than or equal to a certain size
"Treatment" criteria, for choosing more severely
affected patients,

involve milestones of therapy.

Examples

of such milestones are:
- study patients cystoscoped more than an arbitrary
number of times
- study patients who have more than an arbitrary
number of lithotomy operations
The advantages of selecting a reference group by
symptomatic criteria are clear. These criteria are not
influenced by personal opinions of the physician as to
treatment. They probably are the most direct reflections of
disease. The most prominent disadvantage is that most forms
of symptomatic data are difficult to obtain from medical
records.

It would be impossible, for example,

above cited examples of symptomatic criteria.

to use the
Stone sizes

are not measured and mg/24hour excretions of cystine are not
uniformly reported.
"Treatment" criteria for patient selection may be
criticized as being subject, in part, to the whim of
physicians. They may, however, be defended on the grounds that

'

treatment usually is at least a partial reflection of the
severity of disease. Hopefully, physicians acting in good
faith will recommend a therapeutic intervention only when the
severity of disease warrants it. Treatment criteria are relatively
easy-to-use insofar as charts carefully record operations,
cystoscopies, etc..
This writer is acutely aware of the need to select-out
an appropriate reference group of cystinurics to compare the
various modes of therapy.

It is clear that either method of

selecting this group is not without fault. Therefore, we will
select our reference group of "sick" cystinurics in two v/ays:
one using a treatment criteria and one using a symptomatic
criteria. This will generate two reference groups of patient-years.
The indices of rate of lithotomy surgery, stone episodes, etc.
will be measured in both groups.

If the results show the

same trends in both groups, it will strengthen the conclusions
of this thesis.

Some potential critics of our methodology,

were only one method of selecting a patient group to be used, thus
will be denied an objection.
The treatment criterion for selecting patient-years to
be studied is as follows: Those patient-years of patients
following at least one urinary tract lithotomy operation
will be selected as representing a comparable group of
cystinurics. These years will constitute the "treatment
criterion" reference group. The underlying assumption is that
the need to have had surgery suggests relatively severe disease.
Operative procedures are generally easy to identify in medical
histories.

The symptomatic criterion for selecting patient-years
to be studied .is as follows? Those patient-years of
patients following at least one hospital admission or
physician visit for what is identified as renal colic will
be selected as representing a comparable group of
cystinurics, These years will constitute the "symptomatic
criterion

reference group. Renal colic* in its first

appearance * is an identifiable symptom.

By including

hospital admissions and physician visits, we hope to
account for variability in physician willingness to
admit.a patient to the hospital.
It should be noted that no measures of statistical
significance were applied in data analysis. The enthusiasm
with which one interprets the results of this study should
be tempered, therefore, because of the absence of
these statistical measures. The

services of a

biostatistician will be enlisted if any portion of this
thesis comes to subsequent publication.
3. Results
It has been argued, in the immediately preceeding
section, that patients were selected to receive penicillamine
because they had disease unresponsive to more conservative
measures. To test this hypotheses, patient records
were searched to identify the reasons given for
initiating penicillamine in the thirty-two patients
who received the drug. The results are presented
in Table F-l.
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Table F-l
Reasons for Initiating Penicillamine
There were a total of fifty-seven attempts at initiating
this drug in thirty-two individuals.
Indication Given for Initiating
Penicillamine

Number of times
this indication
invoked

%

of 57 Attempts

Objective Evidence of Active Disease
While On Conservative Therapy
Roentgenographic Evidence
31
"Unacceptably" high 24 hour
urinary cystine
4
Crystalluria
3
"Poor renal function" tests
2
Symptoms or Treatment Suggestive of
Uncontrolled Disease While On
Conservative Therapy
Recurrent Colic and/or Stone
Passage
30
S/P Lithotomy Surgery or
19
Nephrectomy
Recurrent UTIs
2
Problems of Patient Management
Penicillamine was newly available
(mid-1960's)
8
It was hoped that addition of a
medication would improve patient
compliance with his/her therapy
3
Necessary amount of fluid intake
was impractical for the patient
2
Surgery had not completely
removed stones
2
Penicillamine was Begun as Part of the
Initial T.herapy of a Patient never
Before Treated
10

54 $
T/o

%

5J/o
W

4 cJo
14#

5%

4%
18 %

Table F-l demonstrates that the principal reason for
initiation of penicillamine was the failure of therapy, in the
absence of the drug, to control disease. This reinforces the
importance of not simply comparing penicillamine to
nonpenicllamine patients.

It was necessary to select a

comparable group of patient-years.
In Table F-2 we present the number of patient-years in

-
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each of the therapeutic categories for a group selected from
our population of cystinurics by the

"symptomatic” criterion.

Table P-2
3ilg-jDlg.tribution of Patient-Years Among the Therapeutic Modalities
Patient-Years of Observation in Patients Following At Least
One Hospital Admission or Physician Visit for Renal Colic
Therapeutic Modality

Number of Patients
Contributing Years
To The Category

Total
PatientYears

Fluids

22 patients

76 patient-years

Fluids/Alkali

22

134.5

Fluids/Penicillamine

18

65.5

Fluids/Alkali/
Penicillamine

12

49.2

The distribution of patient-years was also prepared using
a "therapeutic" criterion.
Table F-3
The Distribution of Patient-Years Among the Therapeutic Modalities
Patient-Years of Observation in Patients who have had At
Least One Lithotomy Operation
Therapeutic Modality

Number of Patients
Contributing Years
To The Category

Total
PatientYears

Fluids

16 patients

60.6 patient-years

Fluids/Alkali

24

189.7

Fluids/Penicillamine

16

77

Fluids/Alkali/
Penicillamine

12

4 7.7

In cornparing tables F-2 and F-3,

we note that for

three of the four modes of therapy there are more patient-years
per mode in Table F-3 than in Table F-2.
to expectation.

This is contrary

Episodes of renal colic ought to predate

lithotomy operations.

Our finding may be explained by the

greater care with which operations

(a treatment) are recorded

in charts than episodes of renal colic

(a symptom),

In

both tables the fluids/alkali method was the most
frequently employed and the fluids/alkali/penicillamine
method was the least frequently used in treating patients.
The distribution of patient-years among the several
therapeutic modalities may

now be employed to evaluate the

relative efficacies of the different modes.

First we will

consider the effect of type of therapy on rate of lithotomy
operation.

This writer suspects that this index in one of

the most reliable. Histories tend to be fastidious in
identifying operations and procedures by type and date.
Operative notes,

anesthesia records,

and pathology reports

further allow careful delineation of each procedure.

Table

F-4 presents the data for the patients selected by the
symptomatic criterion.

'
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Table P-4
The Rate of Lithotomy Surgery
Patient-years following one episode of renal colic
Treatment Modality

Patient-Years

Number
of
Operations

Operations
per
Patient-Year

Fluids

76patient-yrs

10

0.13

Fluids/Alkali

134.5

18

0.13

Fluids/Penicillamine 65.5

2

0.03

Fluids/Alkali/
Penicillamine

0

o

49.2

This data suggests that the addition of penicillamine
to the therapeutic regimen reduces the number of operations
per patient-year.

We may attempt the same calculation using

patient-years selected by the therapeutic criterion and see
if the pattern repeats.
Table F-5
The Rate of Lithotomy Surgery
Patient-years following at least one operation
Treatment Modality

Patient-Years

Number
of
Operations

Operations
per
Patient-Year

Fluids

60,6 patientyears
189.?

4

0.06

22

0.11

Fluids/Penicillamine 77

3

0.04

Fluids/Alkali/
Penicillamine

0

0

Fluids/Alkali

47.7

Irrespective of how the patient-years are selected,
pattern emerges which shows that penicillamine seems to

a

reduce the not-p
upon.

+
v • ,
at which cystinuric individuals are or
are operated
a

Ihe second index n-r +u
„
•
°f therapeutic efficacy which win v,
examined is ra+o
cn Wl11 be
rate of cystoscopy. in TaUe
years are selected by the
’ ^
Patlent“
that
• .
symptomatic criterion, we see
penicillamine reduces the rate at
-e cystoscoped.

^ Cy8tin^«

Table F-6

Ij^-l3te_pf_cyst0Sf,nT,Y
Patient-years following one episode of renal cor
w

TreatmentTreatment Modality

^ Sr 1 OU U

■
Patient-Years

0nal collc
Number
of
Procedures

Fluids

76 patientFluids/Alkali

years

134.5

6

0.07

21

O.I5

Fluids/Penicillamine 65.5
0

Fluids/Alkali/
Penicillamine

40 2
V-2

Procedures
per
PatientTear

0

0
0

Table P-6 suggests that penicilla •
rate of CV8to„
Penicillamine reduces the
cystoscopy. This paUern re
years are selected by the the
Patienty the therapeutic criterion.

'
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Table F-7
The Rate of Cystoscopy
Patient-years following at least one operation
Treatment Modality

Patient-Years

Number
of
Procedures

Procedures
per
PatientYear

Fluids

60.6 patientyears
189.7

3

0.04

22

0.11

Fluids/Penicillamine 77

0

0

Fluids/Alkali/
Penicillamine

0

0

Fluids/Alkali

47.7

The third index which will be used to compare modes of
therapy is the rate of occurrence of renal colic.

We first

present the data of patient-years selected by symptomatic
criteria.
Table F-8
The Rate of Renal Colic
Patient-years following one episode of renal colic
Treatment Modality

Patient-Years

Number
of
Episodes

Episodes
per
PatientYear

Fluids

76 patientyears

21

0.27

Fluids/Alkali

134.5

32

0.23

Fluids/Penicillamine 65.5

12

0.18

Fluids/Alkali/
Penicillamine

4

0.08

49.2

Adding alkali and/or penicillamine to the therapeutic
regimen decreases the episodes of renal colic.

Looking at

the data in the treatment reference group confirms this finding.

Table F-9
The Rate of Renal Colic
Patient-years following at least one operation
Treatment Modality

Patient-Years

Number
of
Episodes

Episodes
per
PatientYear

Fluids

60.6 patientyears
189.?

10

0.16

29

0.15

10

0.13

4

0.08

Fluids/Alkali

Fluids/Penicillamine 77
Fluids/Alkali/
Penicillamine

47.7

Tables F-8 and F-9 suggest that one may decrease the number
of episodes of renal colic by successively adding alkali
and penicillamine to the therapy of cystinuria.
Penicillamine does not, however, appear to be
successful in reducing the rate of episodes of spontaneous
stone passage or of urinary tract infections.
presents the data on spontaneous stone passage

Table F-10
(symptomatic

criterion).
Table F-10
The Rate of Spontaneous Stone Passage
Patient-years following one episode of renal colic
Treatment Modality

Patient-Years

Number
of
Episodes

Episodes per
PatientYear

Fluids

76 patientyears
13^.5

28

O.36

29

0.21

21

0.32

9

0.18

Fluids/Alkali

Fluids/Penicillamine 65.5
Fluids/Alkali/
Penicillamine

49.2

.

70

It is curious that the therapeutic modalities which include
alkali have the lower rates of spontaneous stone passage.
pattern recurrs,

although it is not as striking,

This

if we

look at patient-years selected by the therapeutic criterion.
Table P-11
2Jlo—Ha ce of Spontaneous Stone Passage
Patient-years following at least one operation
Treatment Modality

Patient-Years

Number of
Epi sodes

-Episodes per
Patient-Year

Fluids

60.6 patient-

12

0.19

27

0.14

20

0.26

9

0.18

years
Fluids/Alkali

189.7

Fluids/Penicillamine 77
Fluids/Alkali/
Penicillamine

^7.7

The fiit£i index is the rate of urinary tract
infection.

Urinary tract infections were rarely documented

in the medical records.
gram stains,

By insisting on culture results or

reported either directly or in progress notes,

very few alleged infections were accepted as valid data.
Table F-12 shows that the addition of alkali seems to reduce
the rate of urinary tract infections.
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Table F±12
The Rate of Urinary Tract Infection
Patient-years following one episode of renal colic
Treatment Modality

Patient-Years

Number of
UTIs

UTIs per
Patient-Year

Fluids

76 patient-

7

0.09

8

0.05

Fluids/Penicillamine 65.5

7

0.10

49.2

2

0.04

years
Fluids/Alkali

134.5

Fluids/Alkali/
Penicillamine

The pattern of Table F-12 is repeated when we look at patientyears following at least one lithotomy operation.
Table F-13
The Rate of Urinary Tract Infection
Patient-years following at least one operation
Treatment Modality

Patient-Years

Number of
UTIs

OTIs per
Patient-Year

Fluids

60.6 patientyears
189.7

5

0.08

9

0. 04

Fluids/Penicillamine 77

10

0.13

Fluids/Alkali/
Penicillamine

2

0.04

Fluids/Alkali

47.7

While penicillamine does not appear to be effective in
reducing either the rate of spontaneous stone passage or
the rate of urinary tract infection,

alkali seems to have

a positive effect.
The final index of therapeutic efficacy to be presented
is "roentgenographic evidence of change in stone size or
number." The derivation of this index is explained in the
methods section.

Table F-14 presents the data for the
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symptomatic criterion reference group.

On careful examination,

this table displays an intriguing pattern:

1) Penicillamine

reduces metabolically active urolithiasis measured by
x-rays.

2) Penicillamine increases metabolically stable

urolithiasis as measured by x-rays.

3) Penicillamine

increases the time periods of improving stone disease as
measured by x-rays.
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The reader will notice that no counterpart to Table F-14,
using the

"treatment" criterion,

was prepared.

It is not,

is presented.

Such a table

however, presented because in

excess of 40% of the patient-years in this table fall in the
indeterminate category.

Since these

"indeterminate" years were

unevenly distributed among the treatment modalities,

interpretation

of data from such a table would be impossible.
A possible source of bias in using x-ray studies is an
uneven distribution of time or number of films taken.
example,

For

assume a stone was growing as follows:
size

J

*

0

12

3

4

months
If two films were taken,

at zero and four months, .one would

report four months of metabolically active urolithiasis.
however,
months,

three films were taken at zero,

three,

If,

and four

one would report three months of "stable" activity

and one months of "metabolically active".

If the penicillamine

groups show noticeably more films per patient-year than the
non-penicillamine groups,

they might be biased towards

under-reporting of "increasing" activity.

Table F-15 shows

that the rate of films per patient-year varies slightly by
treatment modality.

Table F-15
The Number of KUBs + Abdominal Films + IVPs + Retrograde
Pyelo,qrams Taken per Patient-Year in Patients Who Have Had
At Least One Episode of Renal Colic
Treatment Modality

Patient-Years

Number
of
Studies

Studies
per
PatientYear

76 patientyears
13^.5

110

1.4

172

1.3

108

1.6

73

1.5

•
Fluids
Fluids/Alkali

Fluids/Penicillamine: 65.5
Fluids/Alkali/
Penicillamine

49.2

The penicillamine treatment groups do have more studies per
patient-year.

It is difficult to imagine, however,

that such

a slight increase in number of x-rays could entirely account
for the striking findings of Table F-14.
4,

Discussion
Crawhall reported on the ability of penicillamine to

reduce urinary cystine concentration in the cystinuric
individual in 1963.

Two years later, McDonald reported

stone dissolution in vivo with the drug. Reports soon
appeared detailing the success of drug therapy in series
ot
10
of twelve
and fourteen patients. Penicillamine found
its
way into the therapy of cystinuria.
Since the introduction of penicillamine,

there has

never been a therapeutic trial carefully comparing the
drug to more conservative means of therapy.

The logistics

of organizing a multicenter randomized double-blind prospective trial are forbidding- and the results would be

76

several years in coming.

One might also expect that clinicians

would be hesitant to withold penicillamine,
believed it was indicated.,

when they

to satisfy the requirements of a

trial.
The principal reason for undertaking this thesis was
to design and conduct a trial of the various forms of
therapy for cystinuria.

The non-concurrent prospective trial

which was done utilized six indices of performance to measure
therapeutic efficacy.

Emerging from the mass of data in tables

F-l through F-15 are three significant findings:
1) Penicillamine,

added to either fluids alone

or fluids plus alkali,
lithotomy surgery,

reduces the rates of

cystoscopy,

and renal colic

in a group of cystinuric patients.
2) Alkalinization,

added to either fluids alone

or fluids plus alkali,

slightly reduces the rates

of spontaneous stone passage and urinary tract
infections.
3) Penicillamine reduces the metabolic activity
of cystine renal stone disease as measured by
x-rays.
Penicillamine appears to be a useful addition to the therapy
of cystinuria when efficacy is measured in the manner
utilized in this study.

.
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G.

The Use of Penicillamine
1.

Goal
To record the drug reactions due to penicillamine and

demonstrate the frequency of these reactions,
manner to avoid and/or treat them,

the best

and the frequency with

which drug reactions prevent the use of penicillamine for
therapy
2.

Methods
Urinary cystine values per twenty-four hours were recorded,

when available,

for all adult patients.

This data was plotted

on a two dimensional graph as a function of penicillamine
dose.

This was done to demonstrate the inverse relation

of penicillamine dose to urinary cystine concentration.
The outcome of fifty-seven attempts to initiate
penicillamine therapy in thirty-two patients were recorded.
An outcome was classified,
the followings
reaction,
patient,

based on chart review,

as one of

1) penicillamine stopped because of drug

2) penicillamine was stopped by a non-compliant
3) penicillamine was stopped because the clinician

felt it had fulfilled its task and was no longer needed,
4) penicillamine was thought by the clinician to be
inefficacious,

5) penicillamine was continued to the end

of the medical record.
A drug reaction was defined as an untoward response
following the onset of drug therapy.

Some drug reactions

are relieved relatively rapidly by cessation of drug
therapy.

They may even dissipate without cessation of

therapy. Many of these reactions are of the immune-complex,
Arthus type

3
(Type III) group ie fever, rash, and joint pain.

The nephrotoxic effects of penicillamine, on the other hand,
can follow the onset of therapy by many months and
dissipate slowly following termination of drug therapy. The
reactions to be counted are defined as follows:
"Fever" greater and 99.6° orally or 100.3°

rectally measured either by the patient
or by medical personel
"Rash" is a maculopapular shin erruption observed
and recorded by a physician.
"Arthropathy" in a patient with no previous history
of joint disorder will be tabulated.
A "disorder of taste and/or smell" will be defined
as the report by the patient of a loss of
olfactory or gustatory acuity or symptoms of
inexplicable sensations of foul or noxious
odors or tastes.
"Leukopenia" is a white blood cell count .of less than
5000 cells/ml3 on at least two occassions in
a patient who had, within six months prior
to therapy, a white count greater than or
equal to
cells/ml^.
"Thrombocytopenia" is a platlet count of less than
150,000/ml3 on at least two occassions in a
patient who, within six months prior to
therapy, had a platlet count of at least
150,000/ml3.
"Proteinuria" is urinary protein greater than
500 mg/day. (There were no patients with
pre-penicillamine urinary protein values
greater than 500 mg/day.)
"Glomerulitis" due to^penicillamine must be renal
biopsy proved.’ ,T1
The date of onset of a side-effect was recorded to
the nearest day following the first dose of penicillamine in
a therapeutic course.
After a documented episode of proteinuria, subsequent

.
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uiinary protein values were recorded so that the resolution
of the side-effect could be documented,
3.

Results
The ability of penicillamine to lower urinary concentration

ol cystine m the cystinuria patient is well-known.
G-l is a composite of urinary cystine values,
adult pa. tients,
dose.

Figure

for seventeen

shown as a function of penicillamine

An inverse relation of penicillamine dose to cystine

concentration is shown.
Clinical efficacy is not synonymous with low urinary
cystine values.

For penicillamine to be useful, patients

must take the drug chronically.

In Table G-2 the outcomes

of fifty-seven attempts to initiate penicillamine in
thirty-two patients are shown.
Table G-2
The..putcomes_of_Fifty-Seven Attempts to Initiate Penicillamine
In__Thirty-Two Patients
The therapy was stopped because of
drug reactions in 29 instances.

(51^)

patient non-compliance in 3 instances.

(5#)

the physician deeming the drug no longer necessary in

the physician deeming the drug inefficacious in 1 instance.
The therapy was continued to the end of the chart in
29 instances. (35%)

It is clear that the majority of courses of therapy can not
be or are not maintained chronically.
Looking at the issue of therapy initiation in,more

(2%)

-

01

detail, we see the dismal record of first attempts at
initiating therapy.
Table G-3
The Outcome of Thirty-Two Initial Attempts to Begin Penicillamine
Therapy in Thirty-Two Patients
The therapy was stopped because of
drug reaction in 18 instances.

(56$)

patient non-compliance in 2 instances.

(6^0

the physician deeming the drug no longer necessary in
3 instances, (9/0
the physician deeming the drug inefficacious in 1 instance.
*

The therapy was continued to the end of the chart in 8
instances. (25/0
It is remarkable that only one-fourth of the patients
started on penicillamine are kept on it through our
follow-up period.
Attempts to start therapy, when the first attempt
failed because of a drug reaction, have a higher success rate.
Table G-4
The Outcome of Twenty-Two Attempts to Start Penicillamine
Therapy when the First Attempt Had Failed Because of

a Drug Reaction
The therapy was stopped because of a
drug reaction in 11 instances.

(5°>)

physician deeming the drug no longer necessary in
1 instance. (5/0
The therapy was continued to the end of the chart in
10 instances. (46$)

(35&)

■

The drug reactions attributable to penicillamine use
in cystinuria are shown in Table G-5. A drug reaction is
counted as occurring a maximum of once per patient. For
example, if penicillamine were administered three times
to an individual, and he/she suffered from a rash each
time, this would be counted as one drug reaction.

This

prevents artificial inflation of statistics - ie we do not
count six drug reactions in an individual who was given the
drug six times by a stubborn physician.
Table G-5
The Side-Effects of Penicillamine in Thirtv-Two Patients
Side-Effect

Number of Episodes

/ of 32

Rash

14

44/

Fever

12

38 %

Proteinuria

11

Pruritus

7

22/

Arthropathy

16/

Adenopathy

5
4

Glomerulitus

3

91°

Taste/Smell

9/

Nausea/Vomiting

3
2

ERG Changes

1

2/

Headache, i.ialaise,
Midepigastric pain

1

2/

Pulmonary Embolus

1

2/

Thrombocytopenia

0

0/

Leukopenia

0

0/

13>

6/

■
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It is particularly distressing that one-third of individuals
taking penicillamine develop documented proteinuria - in
excess of 50° mg/day.
The average dates of onset of the side-effects is
shown in Table G-6.
Table G-6
Average Time of Onset Of Penicillamine

Induced Side-Effects

Side-effects are listed in order of frequency
Side-Effect

Range

Mean

Median

Hash

l"3°days

9*3days

9days

Fever

l~30days

10.5days

9days

Proteinuria

1- 45months

12.3months 5raonths

Arthropathy

6-36days

15*8days

lOdays

Adenopathy

2

lldays

lOdays

Taste/Smell

26-55days

3

?days

40days

Nausea/Vomiting

10-30days

15.8days

13days

EKG Changes

11

- 21days

days

Headache, Malaise, 6-18days
Midepigastric pain

-a-

Pulmonary Embolus

*

8 months

V

* indicates only one value

Penicillamine induced proteinuria resolves following
cessation of the drug.
proteinuric patients,

Serial urine proteins,
are shown in Figure G—7.

data is available for three patients

for seven
Sufficient

(2,3»32) to show complete

resolution of the proteinuria.
The therapy of acute penicillamine drug reactions in
not uniform.

Review of patient records discloses no less than
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eleven different treatments for drug reactions.

The most

frequently used therapeutic intervention is stopping the drug.
Clinicians have also used., however,
steroids,

various combinations of

antihistamines, and dose adjustments in the therapy

of penicillamine side-effects.

A few general principals may

be discerned from studying clinical experience in treating
drug reactions.

It was noted that the serum sickness side

effects

rash,

(fever,

arthropathy,

adenopathy)

fully resolved when the drug was stopped.

always success¬

Proteinuria

was also responsive to removal of penicillamine.

In

the three instances of taste/smell side effects the
co-administration of pyridoxine produced relief.
The management of penicillamine side effects may also
be approached prophylactically.

Clinicians have tried various

dosage schemes to avoid unwanted drug reactions.

The

"conventional" way of initiating therapy begins with a
dose of

250mg/day to 5°°mg/day and rapidly goes to the full

1 or 2 g/day dose.

The

"desensitization" technique begins

with doses in the 10 mg/day to 25 mg/day range.
raised slowly,

every third day,

The dose is

until 1 g/day to 2 g/day is

reached at approximately thirty days.

Using the

"steroid

coverage" method involves co-administration of prednisone
with penicillamine.

In the thirty-two attempts at

starting penicillamine therapy in our population,
dosage initiation was selected in thirty cases.

conventional

The success

rate is essentially that shown previously in Table G-3.
Twenty-two attempts were made to restart therapy when

/
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the first attempt failed because of a drug reaction.

Table

G-8 suggests the value of the desensitization technique of
therapy initiation following a first failure.
Table G-8
Avoidance of Drug Reactions
In twenty-two attempts to start therapy when the first attempt
failed because of drug reaction:
Manner of Dose Initiation
Conventional

Desensitization

All
Others

Therapy stopped for

Therapy not stopped

4.

4

(80%)

2

(2 9%)

7 (70%)

1

(20%)

?

(lOO^b)

10

(100^)

5

Discussion
Goodman and Gilman's pharmacology textbook describes

d-penicillamine as "relatively nontoxic,

and much of the

toxicity reported is attributable to the use of the L or
DL forms."
the case.

The clinical literature suggests that this is not
In an early report on penicillamine in the

treatment of cystinuria,

five out of twelve patients

developed a skin erruption on the eighth to tenth day of
therapy.

The same authors repored that two patients had been

troubled by transient nausea.

Drago,

et al report one out of

three cystinurics treated with penicillamine was affected by
a "confluent macular rash and malaise." The kayo Clinic group
reports on complications of treatment in a population of

O
O

1

(30%)

3

H

other reason

(.57%)
1—1

4

-3-

drug reaction

,,

forty-three patients.

i/i/e may adapt this Mayo Clinic data for

tabular presentation.
Table G-9
Complications of Penicillamine Treatment in the Mayo Clinic
Population of Cvstinurics
■XTL

Adapted by E. Halperin from the article of Dahlberg,

$ of 43
patients

Number of Patients

Side Effect

et al

12

3^V°

Taste Abnormalitie s

6

14 c/o

Proteinuria
Grade")

4

9%

Rash ("occasionally
accompanied by fever
and lymphadenopathy")

("High

Granulocytopenia

1

The data reportea in this thesis confirms preceeding
clinical literature on the spectrum of penicillamine sideeffects.

We report,

of proteinuria.

however,

a distressingly high frequency

One-third of our population developed this

potentially threatening side-effect.

Adams,

et al

first

reported nephrotic syndrome associated with penicillamine
\

therapy of Wilson’s Disease in 1964.

Nephrotoxic effects of

penicillamine in cystinuria were reported by Rosenberg and
Hayslett in 196?.

The histopathology of the renal lesion
■*o.ya

was defined in later studies.

Although the renal lesion

appeared not to be progressive in our population of cystinuric
a death has been reported of a patient who developed
nephrotic syndrome while receiving penicillamine.

Sternlieb and Scheinberg have reported on the

-

■

_•
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side-effects of penicillamine therapy for Wilson's Disease.10*
The type and frequency of these effects differ somewhat from
the cystinuria population.

Table G~10,

adapted from the

work of the Albert Einstein Medical College group,

shows the

most common side-effects of penicillamine when it is used
in the treatment of Wilson's Disease,
Table G-10‘
C^ompiications_oi i enicillamine Treatment in a Population
with Wilson's Disease
Adapted by E,

Halperin from Sternlieb and Scheinberg'0^*

Side-Effect

Number of Patients

°/o of the 33
patients in
the population

Rash

6

18 %

Extravasation of
Blood into skin

6

18 %

Leucopenia

5

15%

Fever

4

12%

Drying and scaling
of skin of face

4

12%

Thrombocytopenia

3

9%

Adenopathy

2

6%

Nausea

2

6%

.
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Summary

A Population of fi f+v

•

.

cystinuria was identified. ^

^ Phenotypic

individuals obt •
^
records of these
duals, obtained from hospital- on «.
s‘«-

f„ ,, ”

characteristics and treatment of c

~r,h“"™

*•

^ °liniCal

proved to'be predominately Caucasian ^ ^

~;:r:
•
,
i“i
m,

„„1>n ass _ “"*• "“*«"« *»

18 years.

°en atlon as approximately

A nonconourrent prospective studv „
determine the most of- + .
Y &S conducted to
st effective mode(s) of +k
eystinuria. Therapy with penicill

•

' ^ ^

reducing the rate of lithot

S~ effeatxve in

-1 colic in our po
"
ai
Population of cystinurics
"

*

“

“*

■«.

«™»

„

«M

b> ’"*»•

«The w

7

ar"‘

*

reduction of urinarv tr + •
binary tract infection
stone passage.

valuable in
°r episodes of spontaneous

Penicillamine is a difficul+ „
b6gUn °n a therapeutic cour-e of th^ ^
~

treatment terminal

^ ^

common side-effects are rash,

«"
^ "*'*

Side-effects may be effectively treated
d-s. The technique of decent

^

P^°teinUria*
"

CeSSation °f the

tution Of the drug in an A
. Zatl°n frequenUy permits instio in an individual who
^
° had Previously had

yo

therapy terminated because of a side-effect.

The type

and frequency of side-effects seen when penicillamine is used
for treatment of cystinuria differ from the spectrum of
side-effects reported when the drug is used in Wilson's
Disease«
Penicillamine has been shown to be useful in the
treatment of cystinuria.

It should, however, be used with

caution because of frequent and potentially severe
side-effects.
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